CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. is a Bethesda, Maryland-based clinical-stage biopharmaceutical company focused on cannabinoid-based therapies for cancer. The company’s current lead programs include Cannabics SR, an oral capsule being developed for advanced cancer and cancer anorexia cachexia syndrome, and RCC-33, a first-in-class candidate for colorectal cancer. CNBX has shifted through several prior business models, including mining and oil and gas, and has operated as a biotech company since 2014. Its research and development work has been conducted through licensed facilities in Israel, while commercialization is intended to rely on licensing and third-party partners rather than an internal sales force. The company is still pre-commercial and has not generated meaningful product revenue from its drug pipeline.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical and pre-clinical oncology assets such as Cannabics SR and RCC-33.
Discovery work on cannabinoid-based therapies and administration routes for cancer.
Potential commercialization model based on out-licensing and strategic collaborations.
Historical laboratory services revenue generated outside the core drug pipeline.
Customers
CNBX’s direct customers are not yet established in the way they would be for a commercial pharmaceutical company, because the business is still in development and has no internal sales infrastructure. In the near term, the relevant counterparties are likely to be clinical trial partners, research collaborators, contract manufacturers, and potential licensing partners that can help advance RCC-33 and other candidates through development. If products are approved, the end customers would be physicians, hospitals, oncology clinics, and patients in cancer indications such as colorectal cancer and advanced cancer/CACS. The company also depends on investors and strategic partners to fund development, since it has limited cash flow and no meaningful operating revenue from product sales. Historical revenue from laboratory services indicates that non-core service customers have also contributed modestly in the past.
Research institutions, CROs, and trial collaborators that support preclinical and Phase I/II development of RCC-33 and other oncology candidates.
Pharmaceutical or biotech companies that may license CNBX intellectual property to commercialize products in the U.S. or abroad.
Oncologists, hospitals, and cancer patients who would be the eventual users of approved cannabinoid-based cancer therapies.
GMP suppliers and outsourced CMC providers that supply active ingredients and technical packages for regulatory filings.
Customers for non-core lab services that produced limited historical revenue while the company was still early stage.
Strategy
CNBX’s strategy is to advance its oncology pipeline through preclinical work and into first-in-human Phase I/II studies, with RCC-33 as the main near-term focus. The company intends to use outsourced GMP manufacturing and third-party CMC support rather than building internal manufacturing infrastructure, which reduces fixed cost but increases dependence on vendors. Management also expects to commercialize primarily through licensing and strategic partnerships, especially outside the United States, because it does not have a sales or distribution organization. A further strategic theme is opportunistically adding programs in high-unmet-need oncology areas through acquisition, collaboration, or internal development. The company’s ability to execute this strategy depends heavily on financing, regulatory progress, and partner availability.
Clinical entry is the key value-creation step for a pre-clinical oncology company and is required to validate the asset.
The company has limited cash flow and needs external capital to fund trials, regulatory work, and operating expenses.
CNBX lacks sales, marketing, and distribution infrastructure, so commercialization depends on third parties.
Geography
CNBX is headquartered in Bethesda, Maryland in the United States, and its corporate decision-making and financing activities are centered there. The company states that its R&D has been conducted in a government-licensed laboratory facility in Israel, making Israel an important operational base for research and regulatory permissions. It also notes that commercialization outside the United States may rely on strategic partners, which would broaden geographic exposure if products progress to market. Because CNBX is still pre-commercial, geography matters more for where research is performed and where regulatory approvals are needed than for current sales concentration. No authoritative country-level revenue split was disclosed in the provided excerpts.
Risks
The most immediate risk is going concern risk, as auditors have expressed substantial doubt about the company’s ability to continue operating without additional financing. CNBX has not generated significant revenue from its core biotechnology business, so its ability to fund development depends on capital markets and investor appetite for early-stage biotech. Regulatory risk is also high because the company must obtain FDA clearance for clinical trials and eventual product approval, while its research activities have also depended on Israeli licensing and approved laboratory settings. Commercial risk is elevated because the company has no sales, marketing, or distribution infrastructure and may need to rely on partners whose incentives and execution it cannot fully control. More broadly, oncology drug development faces scientific failure risk, reimbursement risk, competition from better financed peers, and product liability exposure if a therapy reaches patients.
- Going concern and financing shortfallImpact: CriticalLikelihood: High
Auditors disclosed substantial doubt about the company’s ability to continue as a going concern, and the business requires external capital to fund operations.
Exposure: Corporate liquidity and ability to continue development
- Clinical development failureImpact: HighLikelihood: High
RCC-33 is still pre-clinical/early clinical, so efficacy, safety, and trial execution remain unproven.
Exposure: Lead pipeline asset
- Regulatory approval riskImpact: HighLikelihood: High
The company must satisfy FDA requirements for IND filing, clinical trials, and eventual commercialization.
Exposure: Pipeline progression and time to market
- Commercial partner dependenceImpact: HighLikelihood: Medium
CNBX has no internal sales, marketing, or distribution capability and intends to rely on third parties or licensees.
Exposure: Future revenue realization
- Israel operating and licensing exposureImpact: MediumLikelihood: Low
Research has been conducted in Israel under local licensing, so permissions and cross-border operations are important to execution.
Exposure: R&D continuity
Accounting
Judgemental itemsFinancial statements are prepared on a going concern basis despite substantial doubt, which affects asset and liability classification and investor interpretation.
Impact: High sensitivity to financing assumptions
Historical revenue came from laboratory services, so investors should distinguish service revenue from future drug commercialization revenue.
Impact: Limited and non-recurring revenue base
Reported G&A expense was affected by share-based payment expense, which can be significant for a cash-constrained biotech.
Impact: Non-cash expense affects operating loss
Interest on converted loans affected financial loss in interim results, showing that financing structure can influence reported earnings.
Impact: Can create volatility in non-operating results
Similar listed companies
Publicly listed companies with a comparable business focus.
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Nanobiotix S.A.
NBTX · Pharmaceutical Preparations
Anebulo Pharmaceuticals, Inc.
ANEB · Pharmaceutical Preparations
CNS Pharmaceuticals, Inc.
CNSP · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Last updated: 24/09/2026